![]() ![]() Throughout his career he has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Ciaramella has more than 20 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck. Giuseppe Ciaramella is the President of Beam Therapeutics. ![]() in English with distinction from Yale University.ĭr. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune. He also co-led Agios’s expansion into rare genetic diseases. He helped initiate and lead Agios’ landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple research collaborations in cancer metabolism. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. ![]() Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. ![]() John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. ![]()
0 Comments
Leave a Reply. |